Aulos Bioscience’s Imneskibart Demonstrates Outstanding Phase 2 Activity in Checkpoint Inhibitor-Refractory Melanoma and Lung Cancer, Comparing Favorably With Historical Treatment Benchmarks

On November 6, 2026 Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic, imneskibart (AU-007), reported positive Phase 2 data demonstrating clinical activity with imneskibart-based regimens in heavily pretreated patients with doublet checkpoint inhibitor (CPI)-refractory melanoma and CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC). The findings, presented in two posters at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting in Phoenix, Arizona, demonstrate encouraging and durable anti-tumor activity in heavily pretreated patients with limited treatment options, with progression-free survival outcomes that compare favorably with historical benchmarks for available therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The melanoma results demonstrate strong and durable anti-tumor activity with imneskibart plus low-dose, subcutaneous aldesleukin, with and without nivolumab, in patients whose disease had progressed following prior doublet CPI therapy. The triplet regimen of imneskibart plus low-dose, subcutaneous aldesleukin and nivolumab achieved a median progression-free survival (PFS) of 9.1 months and an objective response rate (ORR) of 28% among 18 response-evaluable patients, including one confirmed complete response. The doublet regimen of imneskibart plus low-dose, subcutaneous aldesleukin without nivolumab achieved a median PFS of 6.9 months and ORR of 29%, including a confirmed complete response lasting more than 32 months. These outcomes are particularly encouraging given that patients had progressed despite prior combination checkpoint inhibitor therapy and received a mean of 2.7 prior lines of treatment in the triplet cohort and 2.4 prior lines in the doublet cohort. Published salvage-treatment studies in anti-PD-1-refractory melanoma reported median PFS of 4.2 months with lenvatinib plus pembrolizumab (LEAP-004) and 2.1 to 3.2 months with nivolumab plus relatlimab (RELATIVITY-020), although these studies included different patient populations. A 2026 multicenter retrospective study by the Dermatologic Cooperative Oncology Group (DeCOG) of 120 heavily pretreated patients with advanced melanoma receiving anti-PD-1 plus lenvatinib reported median PFS of 3.5 months; 98% had previously received ipilimumab plus nivolumab. This provides a particularly relevant, though nonrandomized, historical context for the 9.1- and 6.9-month median PFS outcomes reported here.

The NSCLC results provide additional evidence of imneskibart’s activity across difficult-to-treat, CPI-refractory tumors. In heavily pretreated patients with advanced adenocarcinoma NSCLC, the triplet regimen of imneskibart plus low-dose, subcutaneous aldesleukin and avelumab achieved a median PFS of 5.8 months, a confirmed ORR of 21% and a disease control rate (DCR) of 86%. Median overall survival (OS) had not been reached at a median follow-up of 10.6 months. Patients had received a mean of 2.6 prior lines of therapy, making these results particularly encouraging in a heavily pretreated population with limited remaining options. The 5.8-month median PFS compares favorably with the 3.6-month median PFS for docetaxel in the nonsquamous NSCLC subgroup of the randomized Phase 3 TROPION-Lung01 trial. Patients in the overall TROPION-Lung01 docetaxel arm had received an estimated mean of at least 1.5 prior lines of therapy, compared with 2.6 prior lines in the Aulos adenocarcinoma cohort, underscoring the substantial prior treatment exposure in the Aulos study. These cross-trial comparisons are descriptive and do not establish comparative superiority.

"We believe these are exceptional results for imneskibart in two of the most challenging populations in oncology – melanoma and NSCLC patients whose tumors have progressed despite multiple prior treatments," said Aron Knickerbocker, President and Chief Executive Officer of Aulos Bioscience. "With deep and durable tumor responses, consistent pharmacodynamic activity and manageable safety profiles, these findings provide a compelling foundation for advancing into randomized clinical trials and reinforce our confidence in imneskibart’s differentiated mechanism and its potential to become an important new treatment option in both melanoma and lung cancer."

As of the September 18, 2026 data cutoff, data were available from 51 melanoma patients in the Phase 1 and Phase 2 cohorts, with and without nivolumab, of whom 14 were evaluable for response in the imneskibart doublet cohort and 18 were evaluable for response in the imneskibart triplet cohort. In NSCLC, data were available from 26 patients (with adenocarcinoma or squamous histology) in the Phase 2 avelumab combination cohort, 16 of adenocarcinoma histology, of whom 14 were evaluable for response. Key findings are summarized below.

Remarkable progression-free survival and durable anti-tumor activity in doublet CPI-refractory melanoma, with ongoing deep tumor reductions observed with imneskibart triplet and doublet regimens

Imneskibart triplet regimen:

Median PFS of 9.1 months in patients who received a mean of 2.7 prior lines of therapy.
28% ORR, including one confirmed complete response and four partial responses of -81%, -74%, -65% and -40%.
All but four patients had liver and/or lung metastases at baseline, including all patients who achieved a partial response.
Median OS data remained immature, with 16 of 20 patients alive or censored at the data cutoff and a median follow-up of 5.6 months.
Imneskibart doublet regimen:

Median PFS of 6.9 months in patients who received a mean of 2.4 prior lines of therapy.
29% ORR, with four of 14 patients with the deepest target tumor reductions continuing on treatment for more than one year: -48% (on study for 13 months), -47% (continues on study for 14+ months) and a confirmed complete response (-100%; continues on study, now in follow-up, for 32+ months). One patient with measurable non-target tumors had a -58% reduction in tumor size (on study for 18.5 months).
Nine of 14 patients achieved stable disease.
Median OS was 16.1 months at a median follow-up of 18 months.
Exceptional progression-free survival exceeding historical chemotherapy benchmarks in CPI-refractory advanced adenocarcinoma NSCLC observed with imneskibart triplet

Median PFS of 5.8 months.
21% ORR, with three of 14 patients achieving target tumor reductions of -42% (on study for eight months), -43% (continues on study for 12+ months) and -45% (on study for six months).
Nine of 14 patients achieved stable disease, resulting in an 86% disease control rate.
Patients had received a mean of 2.6 prior lines of therapy before entering the study.
Median OS was not reached at a median follow-up of 10.6 months.
Pharmacodynamic findings continue to support imneskibart’s differentiated mechanism of action

In melanoma, treatment produced sustained reductions in regulatory T cells (Tregs) and increases in CD8/Treg ratios. Patients with Treg reductions greater than the median reduction of 56% experienced longer time to progression than patients with smaller reductions.
Across the melanoma triplet and doublet regimens, durable increases in CD8 T cells and CD8/Treg ratios were accompanied by corresponding decreases in Tregs, supporting imneskibart’s mechanism of redirecting interleukin-2 (IL-2) toward immune effector cells and away from immunosuppressive Tregs.
In NSCLC, CD8/Treg ratios and natural killer (NK) cells increased from baseline substantially, with greater increases associated with longer PFS.
The increase in NK cells may complement avelumab’s antibody-dependent cellular cytotoxicity (ADCC) activity. Avelumab is an anti-PD-L1 antibody with an active Fc domain and ADCC effector function mediated by NK cells; on average, imneskibart increased NK cell counts nearly three-fold from baseline.
Imneskibart-based regimens continue to demonstrate manageable safety profiles

Most drug-related adverse events were Grade 1 or 2 with imneskibart and low-dose, subcutaneous aldesleukin, alone or in combination with nivolumab or avelumab.
No capillary leak syndrome or treatment-related deaths were observed.
The emerging safety profile of the doublet and triplet regimens in melanoma and NSCLC is consistent with the known safety profiles of nivolumab and avelumab with imneskibart plus aldesleukin, with no new toxicity signals observed.
Enrollment is complete in all Phase 2 cohorts evaluating nivolumab or avelumab plus imneskibart and low-dose, subcutaneous aldesleukin.

The posters, "Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: Phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)" (Abstract 605) and "Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing Phase 1/2 study" (Abstract 611) are accessible to meeting registrants as an electronic poster on the SITC (Free SITC Whitepaper) Annual Meeting virtual platform. They are also available on the Aulos Bioscience website in the Abstracts and Publications section.

To learn more about the imneskibart clinical trial program, please visit ClinicalTrials.gov (identifier: NCT05267626). For patients and providers in the U.S., please visit www.solidtumorstudy.com. For patients and health professionals in Australia, please visit www.solidtumourstudy.com.

About Imneskibart
Imneskibart (AU-007) is a human IgG1 monoclonal antibody designed by leveraging artificial intelligence that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, imneskibart redirects IL-2 to reinforce anti-tumor immune effects. This is achieved by preventing IL-2, either exogenous or secreted by effector T cells, from binding to trimeric receptors on regulatory T cells while still allowing IL-2 to bind and expand effector T cells and NK cells. This prevents the negative feedback loop caused by other IL-2-based treatments and biases the immune system toward activation over suppression. Imneskibart also prevents IL-2 from binding to CD25-containing receptors on eosinophils, as well as vasculature and pulmonary endothelium, which may significantly reduce the vascular leak syndrome and pulmonary edema associated with high-dose IL-2 therapy.

(Press release, Aulos Bioscience, NOV 6, 2026, View Source [SID1234674387])

Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio

On November 6, 2026 Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, reported clinical and biomarker data from three poster presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 41st Annual Meeting, taking place November 4—8, 2026, in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Across the presentations, data from aglatimagene and linoserpaturev highlight systemic and tumor-localized immune effects, biomarker associations with longer survival, and updated survival outcomes across localized prostate cancer, NSCLC, and recurrent glioblastoma. Collectively, the findings inform Candel’s planned biologics license application (BLA) for aglatimagene in localized prostate cancer, support the biological rationale for the ongoing phase 3 AURORA trial in metastatic non-squamous NSCLC, and guide the continued development of linoserpaturev in recurrent glioblastoma.

Aglatimagene in Localized Prostate Cancer (Phase 2)

PrTK05 is a phase 2 trial (NCT07332000) designed to characterize the immunologic effects, viral shedding, and biodistribution of aglatimagene plus standard-of-care (SoC) external beam radiation therapy (EBRT), with or without androgen deprivation therapy (ADT), compared with SoC EBRT, with or without ADT, in patients with localized intermediate-risk prostate cancer. At the data cutoff (October 16th), flow-cytometry analyses included up to 17 patients who received aglatimagene plus valacyclovir and SoC and up to seven patients in a concurrently enrolled SoC-only cohort. Peripheral blood samples were collected at baseline and after each injection through Weeks 16-18.

Key findings included:

CD8+ cytotoxic T cells in peripheral blood increased at the 2-6-week assessments after the first injection (p<0.05), including central memory T cells (TCM; p<0.05) and effector memory T cells (TEM; p<0.05). These cell populations declined in the SoC-only group.

Activated, proliferating CD8+ GZMB+ Ki67+ T cells increased sharply 2-3 weeks after the first injection (p<0.0001) and remained above baseline through Weeks 16-18. No increase was observed after SoC alone.

Serum levels of granzyme A, granzyme B, and perforin increased 2-3 weeks after the first injection of aglatimagene (p<0.05).
Together, these results suggest systemic immune activation following intraprostatic administration of aglatimagene and are consistent with previous observations in glioblastoma, pancreatic cancer, and NSCLC.

PrTK05 data show transient detection of aglatimagene vector DNA in peripheral blood after intraprostatic administration of aglatimagene and clearance in urine samples at weeks 16-18. These findings are consistent with transient systemic biodistribution and shedding following administration.

"The PrTK05 findings show that adding aglatimagene to standard-of-care can generate a systemic cytotoxic T-cell response that was not observed with radiation-based standard of care alone," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel Therapeutics. "Together with biodistribution and shedding results that are consistent with our earlier studies, these data strengthen the mechanistic package we plan to include in the BLA submission for aglatimagene in localized prostate cancer."

Aglatimagene in Progressive NSCLC (Phase 2a)

The SITC (Free SITC Whitepaper) presentation reports additional biomarker analyses from the phase 2a trial of aglatimagene in non-squamous NSCLC published in the Journal for ImmunoTherapy of Cancer on October 1, 2026.

The trial (NCT04495153) included 46 patients in the per-protocol population with stage III/IV NSCLC who had stable or progressive disease despite immune checkpoint inhibitor treatment. Median overall survival was 25.4 months; 23 patients (50%) were alive at 24 months, and six patients (13%) survived beyond 50 months.

New analyses presented at SITC (Free SITC Whitepaper) showed that aglatimagene treatment was associated with:

Longitudinal analyses demonstrated increases in T-cell repertoire diversity over time, consistent with broadening of the adaptive immune response.

Post-treatment tumor biopsies demonstrated increased expression of genes associated with cytotoxic T-cell activation, consistent with enhanced local antitumor immune activity.

Increases in CD40L, NCR1, CXCL5, and granzyme B levels were significantly associated with survival beyond 24 months.
Abundant antigen-presenting cells and monocyte/macrophage-rich myeloid niches in tumor biopsies that were also associated with survival beyond 24 months.
"These multi-omic analyses connect longitudinal immune changes in blood and tumor tissue with clinical outcomes in patients whose disease had remained stable or progressed despite checkpoint inhibition," said Garrett Nichols, M.D., Chief Medical Officer of Candel Therapeutics. "Although these findings are associative, their consistency across complementary biomarker measures adds to the biological rationale for evaluating aglatimagene in the ongoing phase 3 AURORA trial in metastatic non-squamous NSCLC."

Linoserpaturev in Glioblastoma (Phase 1b)

Linoserpaturev is a first-in-class oncolytic herpes simplex virus-1 immunotherapy being evaluated in an ongoing phase 1b trial in recurrent high-grade glioma (rhGG), including glioblastoma (NCT03152318). The SITC (Free SITC Whitepaper) poster reports updated overall survival from single- and repeat-administration cohorts.

In Arms A+B, 50 patients received 51 intratumoral injections, including one patient who received two injections. Median overall survival was 12.0 months (95% CI, 8.3-14.4), with median follow-up of 68.6 months. Eleven of 50 patients (22%) were alive at 18 months, eight (16%) at 24 months, five (10%) at 36 months, and two (4%) at 48 months, as of the August 14, 2026 data cutoff.
In Arm C, 12 patients with recurrent glioblastoma received up to six administrations of linoserpaturev. Median overall survival was 14.3 months (95% CI, 8.9 months-not reached), with median follow-up of 15.3 months. Five of 12 patients remained alive at the July 13, 2026 efficacy cutoff. These survival data remain immature, and six patients had only recently initiated treatment and therefore had limited follow-up at the cutoff.
The survival observed following single and repeated administration supports continued evaluation of linoserpaturev as a monotherapy in recurrent glioblastoma. Previously reported spatial profiling showed persistent CD4+ and CD8+ T-cell infiltration after linoserpaturev treatment and identified VEGFA-high hypoxic regions with relatively poor T-cell infiltration.

Based on that observation, an exploratory retrospective analysis evaluated overall survival among patients who received bevacizumab, an anti-VEGFA therapy, after linoserpaturev. Of 41 patients treated with a single linoserpaturev injection, 28 subsequently received bevacizumab. The analysis did not show a statistically significant overall survival improvement (p=0.7793), although a delayed initial decline in survival probability was observed among patients who received bevacizumab. Because bevacizumab use was not protocol defined and the analysis was retrospective and non-randomized, the findings do not establish treatment benefit. They provide a hypothesis-generating basis for prospective evaluation of treatment sequence and timing.

"The updated survival data following both single and repeated linoserpaturev administration are encouraging in a disease with persistently poor outcomes," said Francesca Barone, M.D., Ph.D., Chief Scientific Officer of Candel Therapeutics. "Importantly, the tissue analyses are also helping us identify biologically grounded strategies that may further enhance and sustain antitumor activity. The bevacizumab analysis is exploratory and does not establish benefit, but it provides a clear hypothesis for prospective evaluation as we refine the development strategy for linoserpaturev in recurrent glioblastoma."

About aglatimagene besadenovec

Aglatimagene besadenovec (aglatimagene), Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumor. After intratumoral administration, HSV-tk enzyme activity results in conversion of prodrug (valacyclovir) into deoxyribonucleic acid (DNA)-incorporating nucleotide analogs, leading to immunogenic cell death in cells exhibiting DNA damage and proliferating cells, with subsequent release of a variety of tumor (neo)antigens in the tumor microenvironment. At the same time, the adenoviral serotype 5 capsid proteins promote inflammation through the induction of expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Aglatimagene has the potential to treat a broad range of solid tumors. The Company completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) with results published in the Journal for ImmunoTherapy of Cancer, and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA) and published in The Lancet Oncology. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC. More than 1,000 patients have been dosed with aglatimagene in clinical trials with a favorable tolerability profile to date, supporting the potential for use with standard of care, when indicated. Aglatimagene is currently not approved by the FDA or any other regulatory authority for any use.

About linoserpaturev

Linoserpaturev is a first-in-class, replication-competent, next-generation oncolytic herpes simplex virus-1 (HSV-1) immunotherapy candidate designed for dual activity for oncolysis and immune activation in a single therapeutic. In October 2023, the Company announced that Nature published results from the ongoing clinical trial where linoserpaturev was reported to be generally well-tolerated with no dose-limiting toxicity. In the clinical trial, the investigators observed improved median overall survival compared to historical controls after a single linoserpaturev injection in this therapy-resistant condition1. The Company and academic collaborators are currently supported by Break Through Cancer to evaluate the effects of repeated linoserpaturev injections in patients with recurrent glioblastoma in an expansion cohort from the phase 1b clinical trial. In October 2025, an original manuscript, published in Science Translational Medicine reported collected findings from a comprehensive analysis of 97 serial tumor biopsies collected from two patients treated with repeated administrations of linoserpaturev in arm C. Lastly, in February 2026, Cell published an original manuscript showing that a single linoserpaturev treatment triggered persistent T-cell infiltration and antitumor immunity against glioblastoma, with key immune features associated with longer survival. Linoserpaturev previously received Fast Track Designation and Orphan Drug Designation for the treatment of rHGG from the FDA.

(Press release, Candel Therapeutics, NOV 6, 2026, View Source [SID1234674405])

Indapta Therapeutics Announces Oral Presentation of Clinical Proof-of-Concept Data for IDP-023 Allogeneic g-NK Cell Therapy Plus Isatuximab in Heavily Pretreated Multiple Myeloma at 2026 Annual Meeting of Society for Immunotherapy of Cancer

On November 6, 2026 Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, reported that complete Phase 1 data for IDP-023, the Company’s allogeneic g-NK cell therapy, in combination with isatuximab in patients with relapsed/refractory multiple myeloma (RRMM) will be featured in an oral presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting, taking place November 4–8, 2026, in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are highly encouraged to have achieved clinical proof-of-concept in these very advanced patients," said Dr. Mark Frohlich, CEO of Indapta. "The patients in this cohort had exhausted most available options: all were refractory to daratumumab, two-thirds had received prior CAR-T therapy, and two-thirds had received a T-cell engager. These data support our preclinical hypothesis that IDP-023 can rescue patients with resistance to CD38-directed therapy. After recent feedback from the FDA, we are planning an expansion cohort in our current trial followed by a randomized registration-enabling trial in highly refractory patients with multiple myeloma."

Oral Presentation Details

Title: IDP-023 Allogeneic g-NK Cells Combined with Isatuximab in Relapsed/Refractory Multiple Myeloma: Complete Safety, Efficacy, and Tumor Microenvironment Remodeling from a Phase 1/2 First-in-Human Study
Session: Clinical Oral Abstract Session
Date and Time: Friday, November 6, 2026, 12:00 PM – 12:15 PM, MST
Presenter: Mark W. Frohlich, MD, Indapta Therapeutics
Location: Phoenix Convention Center, Phoenix, Arizona, Halls BC

Poster Presentation Details

Abstract Number: 1185
Date and Time: Friday, November 6, 2026, 12:15–1:45 PM and 5:30–7 PM MST
Location: Phoenix Convention Center, Phoenix, Arizona, Poster Hall

The presentation summarizes safety and efficacy results from the Phase 1 portion of the ongoing Phase 1/2 trial (NCT06119685), focusing on 12 patients treated with IDP-023 in combination with isatuximab, an anti-CD38 monoclonal antibody approved for the treatment of multiple myeloma, together with translational analyses of the bone marrow tumor microenvironment. Patients received three doses of IDP-023 per cycle (10-20 billion cells per dose) with interleukin-2 (IL-2). Select patients received additional cycles. Patients were heavily pretreated, with a median of 6.5 prior lines of therapy (range 2–17); all were refractory to daratumumab, 92% were triple-class refractory, 58% were penta-refractory, 83% had received prior BCMA-directed therapy, 67% had received prior CAR-T therapy, and 67% had received a prior T-cell engager. All patients with available cytogenetics had high-risk disease (80% ultra-high risk), and 25% had extramedullary disease.

Key highlights from the oral presentation include:

The overall response rate (ORR; partial response or better) was 45% (5 of 11 response-evaluable patients) per 2026 International Myeloma Working Group (IMWG) criteria, and median progression-free survival (mPFS) was 6.3 months (95% CI, 2.0–not reached), compared with a 0% ORR and 1.6-month mPFS reported for isatuximab monotherapy in daratumumab-refractory patients (Mikhael et al., Blood Cancer Journal 2021).
A 72-year-old patient with ultra-high-risk cytogenetics, bulky extramedullary disease, and 10 prior lines of therapy, including BCMA CAR-T and two T-cell engagers, achieved a stringent complete response for > 1 year, with complete resolution of extramedullary disease on PET/CT.
Treatment was generally well-tolerated, with no dose-limiting toxicities through dose level 3 (20 billion cells, the maximum dose tested), no treatment-related deaths or discontinuations, and no clinically significant cytokine release syndrome, ICANS, infections, or bleeding. The most common adverse events were cytopenias related to lymphodepleting chemotherapy, which had predictable onset and from which all patients recovered.
Analysis of paired pre- and post-treatment bone marrow samples from 12 patients showed a trend toward increased CD8+ and gamma-delta T cells and decreased myeloid-derived suppressor cells following IDP-023, suggesting that IDP-023 may remodel the tumor microenvironment in a manner that supports durable responses and could complement subsequent T-cell-directed therapies such as T-cell engagers.
Based on these results and an End-of-Phase 1 Type B meeting with the U.S. Food and Drug Administration (FDA) in July 2026, Indapta plans to extend its Phase 1 trial to include a cohort of 15–20 highly refractory patients matching its proposed indication, using a fixed dose and schedule of up to three treatment cycles.

Indapta’s Proprietary g-NK Cell Therapy

Indapta’s universal, allogeneic NK cellular immunotherapy platform consists of a potent subset of naturally occurring NK cells, known as "g minus" NK cells, or "g-NK" cells. g‑NK cells arise from epigenetic changes resulting from exposure to cytomegalovirus (CMV). To generate IDP-023, Indapta preferentially expands g-NK cells from healthy donors, with low donor to donor variability. IDP-023 has several differentiated mechanisms of killing target cells without the need for genetic engineering, including highly robust antibody-dependent cell mediated cytotoxicity (ADCC), the targeting of HLA-E expressing cells via the NKG2C receptor, and the inherent anti-viral activity of g-NK cells.

Indapta’s g-NK cells can release dramatically more immune activating cytokines and cell-killing compounds than conventional NK cells. In preclinical studies, IDP-023 has demonstrated more potent and durable antitumor activity when combined with cancer targeting monoclonal antibodies as compared to conventional NK cells. (Bigley et al., Blood Advances 2021, View Source). g-NK cells in combination with a B cell targeting antibody can also deplete normal B cells from healthy donors or patients with autoimmune disease.

(Press release, Indapta Therapeutics, NOV 6, 2026, View Source [SID1234674421])

Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones

On November 6, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, reported its participation in BIO-Europe 2026, taking place November 9–11 in Cologne, Germany, with additional digital partnering sessions scheduled for November 17–18. BIO-Europe 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Sari Fishman, Vice President of Business Development, will represent Can-Fite at the conference, focusing on potential licensing agreements, co-development arrangements, commercialization partnerships, and other strategic transactions aimed at unlocking the commercial value of the Company’s advanced clinical pipeline.

Can-Fite enters BIO-Europe following a series of clinical and intellectual property developments that have strengthened its portfolio and expanded potential partnering opportunities across multiple therapeutic areas.

Key assets and partnering opportunities include:

• Namodenoson – Pancreatic Cancer: Final positive Phase IIa results, presented at ESMO (Free ESMO Whitepaper) 2026, demonstrated a favorable safety profile and encouraging exploratory survival findings in heavily pretreated patients, supporting further clinical development.

• Namodenoson – Liver Cancer: An ongoing pivotal Phase III study in advanced hepatocellular carcinoma (HCC), with longer-than-anticipated blinded overall survival observed across the study population. An interim analysis is planned.

• Piclidenoson – Psoriasis: A pivotal Phase III program that has reached its prespecified interim analysis stage, with results expected in the first quarter of 2027.

• Namodenoson – MASH: An ongoing Phase IIb clinical development program targeting a significant global market opportunity.

• Piclidenoson – Lowe Syndrome: A rare disease development program supported by a collaboration with Fondazione Telethon and recently strengthened by a Eurasian patent allowance covering Lowe syndrome and Dent disease 2.

Can-Fite has already established multiple regional licensing agreements, generating approximately $20 million in upfront and milestone payments to date, with the potential for additional milestones and royalties. The Company intends to build on this commercial track record by pursuing additional regional and broader strategic partnerships.

"BIO-Europe provides an important opportunity to translate our recent clinical and intellectual property progress into strategic business discussions," said Dr. Sari Fishman, Vice President of Business Development at Can-Fite BioPharma. "With two pivotal Phase III programs, encouraging new clinical data in pancreatic cancer, and an expanding portfolio of development and commercialization opportunities, we believe Can-Fite offers potential partners access to differentiated clinical-stage assets across several major therapeutic markets. Our objective is to pursue licensing and strategic collaborations that can accelerate development, expand global commercialization opportunities, and create long-term value for our shareholders."

BIO-Europe is one of the biopharmaceutical industry’s leading international partnering events, bringing together pharmaceutical companies, biotechnology developers, investors, and business development executives from around the world.

Dr. Fishman will be available for partnering discussions throughout the conference.

(Press release, Can-Fite BioPharma, NOV 6, 2026, View Source [SID1234674388])

IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer

On November 6, 2026 IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, reported new translational data from its randomized Phase 2 OVATION 2 study of IMNN-001 in newly diagnosed advanced ovarian cancer. The data are being presented in a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting (SITC 2026), being held November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The analysis evaluated paired tumor biopsies collected at screening laparoscopy and at interval debulking surgery from patients in both arms of OVATION 2, using 21 immune markers assessed by cyclic immunofluorescence. The results show that the addition of IMNN-001 to standard-of-care neoadjuvant and adjuvant chemotherapy (N/ACT) was primarily responsible for increased anti-tumoral T-cell activity, as measured by increases in the CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both the tumor and the stroma. Higher CD8+/Treg and CD8+/CD4+ ratios have been associated with improved patient outcomes in other studies. The chemotherapy component of the regimen contributed a complementary effect, supporting proinflammatory macrophage polarization and decreasing myeloid infiltration, particularly in the tumor.

These findings provide additional evidence that the combination of IMNN-001 with N/ACT favors the switch of the tumor microenvironment from immunologically "cold" to "hot," supporting both the activation and the persistence of a T-cell immune response while suppressing pro-tumor myeloid cells. The findings corroborate translational results previously reported from the Phase 1 OVATION 1 study and provide a mechanistic rationale for the clinical benefit observed in OVATION 2, in which IMNN-001 improved final median overall survival by 14.7 months (45.1 months versus 30.4 months) compared with the standard-of-care control arm and median progression-free survival by three months.

"This data provides a compelling immunological explanation for the survival benefit we observed in OVATION 2," said Stacy R. Lindborg, Ph.D., president and chief executive officer of IMUNON. "Seeing a consistent, treatment-driven shift in the tumor immune microenvironment in patient biopsies, rather than in a preclinical model, is an important validation of our TheraPlas platform. Presenting this work at SITC (Free SITC Whitepaper), the premier forum for cancer immunotherapy, reflects the growing scientific interest in our approach as we advance the pivotal Phase 3 OVATION 3 trial."

"The central challenge in epithelial ovarian cancer has been its highly immunosuppressive tumor microenvironment, which has limited the effectiveness of immune therapies such as checkpoint inhibitors," said Douglas V. Faller, M.D., Ph.D., chief medical officer of IMUNON. "What these paired serial patient biopsies show is that IMNN-001 delivers IL-12 where it is needed and dramatically remodels local immune balance in favor of the patient (from "cold" to immunologically "hot"), with minimal systemic IL-12 exposure and a highly favorable safety and tolerability profile. The complementary contributions of IMNN-001 and chemotherapy observed in this analysis help explain why this combination has translated into a survival benefit in the clinic."

The Phase 3 OVATION 3 trial (NCT06915025) is currently enrolling and is designed to confirm the safety and survival benefit of IMNN-001 in frontline advanced ovarian cancer. The trial will also extend the immunological translational research program described in the poster.

Presentation Details

IMNN-001-mediated therapeutic delivery of IL-12 plasmid to tumor tissue and tumor microenvironment, promotes activation and persistence of T-cells which translates to a survival benefit in the clinic
Presenting author: Dr. Douglas Faller, IMUNON, Inc.
Abstract/Poster number: 478
Session: Poster Session 2, Saturday, November 7, 2026, 10 a.m.–2 p.m. and 6–8:10 p.m. MST
Location: Phoenix Convention Center, Phoenix, Arizona
The poster will be available on the Scientific Presentations section of the IMUNON website at www.imunon.com following the presentation.

About the OVATION 2 Study

The OVATION 2 Study (NCT03393884) was a randomized, controlled Phase 1/2 trial evaluating IMNN-001 (100 mg/m2 administered intraperitoneally weekly) in combination with standard-of-care neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin, compared with N/ACT alone, in 112 patients with newly diagnosed Stage III/IV epithelial ovarian cancer. The study included the collection of paired tumor tissue at screening laparoscopy and at interval debulking surgery to support translational research.

About the Phase 3 OVATION 3 Trial

The pivotal Phase 3 OVATION 3 trial is evaluating intraperitoneal IMNN-001 at 100 mg/m² in combination with standard-of-care neoadjuvant and adjuvant chemotherapy versus chemotherapy alone in patients with newly diagnosed Stage IIIB/C or IV epithelial ovarian, fallopian tube or primary peritoneal cancer. The trial is enrolling an all-comers population that includes both homologous recombination-deficient and homologous recombination-proficient patients; eligible patients who respond to first-line platinum-based chemotherapy will proceed to PARP inhibitor maintenance according to applicable guidelines and prescribing information. The primary endpoint is overall survival, with secondary endpoints including chemotherapy response score, surgical response score at interval debulking surgery, time to second-line treatment or death, and objective response rate.

About IMNN-001 Immunotherapy

Designed using IMUNON’s proprietary TheraPlas platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity, acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer, and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel neoadjuvantly in patients with newly diagnosed ovarian cancer. IMUNON previously reported positive results from the completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer.

About Epithelial Ovarian Cancer

Epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every year and approximately 70% are diagnosed in advanced stage III/IV. Epithelial ovarian cancer is characterized by dissemination of tumors in the peritoneal cavity with a high risk of recurrence (75%, stage III/IV) after surgery and chemotherapy. Since the five-year survival rates of patients with stage III/IV disease at diagnosis are poor (41% and 20%, respectively), there remains a need for a therapy that not only reduces the recurrence rate but also improves overall survival. The peritoneal cavity of advanced ovarian cancer patients contains the primary tumor environment and is an attractive target for a regional approach to immune modulation.

(Press release, IMUNON, NOV 6, 2026, View Source [SID1234674406])